PRODUCTNOTEIPO

Note:EdelweissBrokingLtd.isasubsyndicatememberintheissue;accordingly,thisnoteispreparedbasedontheRHPforinformativepurposeonly.

ADVANCED ENZYME TECHNOLOGIES LIMITED

Public Issue of Equity Shares

Issue Highlights
Offer Size:

Fresh Issue of [] Equity Shares aggregating

upto ` 500 Million & OFS upto 40,34,470
Equity Shares out of which Employee
Reservation Portion Upto [] Equity Shares
aggregating upto ` 20 million.

Issue opens:

Wednesday, July 20, 2016

Issue closes:

Friday, July 22, 2016

Price Band:

` 880 - ` 896

Bid Lot:

16 Equity Shares and multiple thereof

Face Value:

Rs.10/-

Discount:

` 86 per Equity Shares to Eligible Employees

Listing:

BSE & NSE

QIB

50%

201.52

204.74

Registrar:

Link Intime India Private Limited

NIB

15%

60.46

61.42

Payment:

Compulsorily ASBA Mode

Retail

35%

141.06

143.32

Total Net Offer

100%

403.03

409.49

NetOfferBreakup:

Category

Allocation

Issue Size ( ` in Crs) at

Lower Band

Upper Band

Promoters of Company
MR. VASANT LAXMINARAYAN RATHI AND MR. CHANDRAKANT LAXMINARAYAN RATHI

Business Overview
Advanced Enzyme Technologies Limited is the largest Indian enzyme company, engaged in the research and development,
manufacturing and marketing of 400+ proprietary products developed from 60 indigenous enzymes.
Having more than two decades of fermentation experience in the production of enzymes, the Company rank among the top 15 global
companies in terms of enzyme sales, and have the second highest market share domestically, next only to the worlds largest enzyme
company Novozymes. The Company operates in two primary business verticals namely Healthcare & Nutrition (human and animal)
and Bio-Processing (food and non-food). Company offers these products to their global clientele of more than 700 customers
spanning presence across 50 countries worldwide. Company supply these value-added and eco-safe enzyme products to diverse
end-user industries like human healthcare and nutrition, animal nutrition, food processing, baking, dairy and cheese processing, fruit
and vegetable processing, cereal extraction, brewing, grain processing, protein processing, oil and fat processing, biomass
processing, textile processing, leather processing, paper & pulp processing, bio-fuels, bio-catalysis etc. Although they have the
capability to manufacture enzymes using all the four natural origins viz. plant, animal, bacterial and fungal, our major focus is on
developing enzymes through microbial fermentation.

Object of the Issue

The Offer consists of a Fresh Issue by Company and an Offer for Sale by the Selling Shareholders.
Offer for Sale: Company will not receive any proceeds from the Offer for Sale.
Fresh Issue: Out of ` 50 Crores proposed to be raised as Fresh Issue, around ` 40 Crores i.e. 80% of the proceeds of the Fresh
Issue shall be used towards the following objects:
1. Investment in Advanced Enzymes USA, companys wholly owned subsidiary for repayment / pre-payment of certain loans availed
by Advanced Enzymes USA; and
2. General Corporate Purposes.
In addition to the aforementioned Objects, Company expects to receive the benefits of listing of its Equity Shares on the Stock
Exchanges, including among other things, enhancing the visibility of Company and brand.

PRODUCTNOTEIPO
Comparison with listed Industry peers
There are no listed entities in India which are similar to the line of business and comparable to Companys scale of operations
(Rs. In Millions)

Consolidated Statement of Profit and Losses, as restated

Particulars

FortheyearendedMarch31,

TotalIncome
TotalExpenditure
ProfitBeforeTax
ProfitafterTax
E.P.S.(Rs.)Basic
E.P.S.(Rs.)Diluted
RONW(%)

2016

2015

2014

2013

2012

2,946.37
1,721.05
1,225.32
784.35
36.03
36.03
28.14

2,242.69
1,505.20
737.49
501.02
23.01
23.01
23.85

2,404.81
1,587.32
277.51
200.86
9.23
9.23
12.07

2,241.15
1,479.57
761.58
492.19

1,748.78
1,271.97
476.81
333.36

An indicative timetable in respect of the Issue is set out below:

Finalization of Basis of Allotment with the Designated Stock Exchange
On or about July 27, 2016
Initiation of refunds/un-blocking of ASBA Accounts
On or about July 28, 2016
Credit of Equity Shares to demat accounts of Allottees
On or about July 29, 2016
Commencement of trading of the Equity Shares on the Stock Exchanges
On or about August 01, 2016
The above timetable is indicative and does not constitute any obligation on Company or the Selling Shareholders or the BRLMs.

RetailPaymentChartAdvancedEnzymeTechnologiesLimited
IssueDates
PriceBand
BidLot
No.ofShares
16
32
48
64
80
96
112
128
144
160
176
192
208

20Jul2016to22Jul2016
INR880INR896
16EquityShares&inmultiplesthereafter
CutoffpricepershareRs.896
TotalAmount(Rs.)
896
14,336
896
28,672
896
43,008
896
57,344
896
71,680
896
86,016
896
1,00,352
896
1,14,688
896
1,29,024
896
1,43,360
896
1,57,696
896
1,72,032
896
1,86,368

Edelweiss Financial Products Distribution Branch Location for submission of application Forms
West
Gujarat

Mumbai Fort, Borivali, Santacruz, Ghatkopar and Pune

Ahmedabad & Surat

North

Delhi (CP) & Jaipur

South

Hyderabad , Bangalore & Chennai

East

Kolkata

Get in touch with us:

1-800-2666001 (Toll-free)

edelweisspartners@edelweissfin.com

www.edelweisspartners.com

PRODUCTNOTEIPO

Disclaimer:
ThisdocumenthasbeenpreparedbyEdelweissBrokingLimited(Edelweiss).Edelweissanditsholdingcompanyandassociatecompaniesareafullservice,integratedinvestmentbanking,
portfoliomanagementandbrokeragegroup.Ourresearchanalystsandsalespersonsprovideimportantinputintoourinvestmentbankingactivities.Thisdocumentdoesnotconstitutean
offerorsolicitationforthepurchaseorsaleofanyfinancialinstrumentorasanofficialconfirmationofanytransaction.Theinformationcontainedhereinisfrompubliclyavailabledataor
othersourcesbelievedtobereliable,butwedonotrepresentthatitisaccurateorcompleteanditshouldnotbereliedonassuch.Edelweissoranyofitsaffiliatesshallnotbeinanyway
responsibleforanylossordamagethatmayarisetoanypersonfromanyinadvertenterrorintheinformationcontainedinthisdocument.Thisdocumentisprovidedforassistanceonly
andisnotintendedtobeandmustnotalonebetakenasthebasisforaninvestmentdecision.Theuserassumestheentireriskofanyusemadeofthisinformation.Eachrecipientofthis
documentshouldmakesuchinvestigationasitdeemsnecessarytoarriveatanindependentevaluationofaninvestmentinthesecuritiesofcompaniesreferredtointhisdocument
(includingthemeritsandrisksinvolved),andshouldconsulthisownadvisorstodeterminethemeritsandrisksofsuchinvestment.Theinvestmentdiscussedorviewsexpressedmaynot
besuitableforallinvestors.Weandouraffiliates,officers,directors,andemployeesmay:(a)fromtimetotime,havelongorshortpositionsin,andbuyorsellthesecuritiesthereof,of
company(ies)mentionedhereinor(b)beengagedinanyothertransactioninvolvingsuchsecuritiesandearnbrokerageorothercompensationoractasadvisororlender/borrowerto
suchcompany(ies)orhaveotherpotentialconflictofinterestwithrespecttoanyrecommendationandrelatedinformationandopinions.Thisinformationisstrictlyconfidentialandis
being furnished to you solelyfor your information.This information shouldnotbe reproduced or redistributed orpassedondirectly or indirectly inany form toany otherperson or
published,copied,inwholeorinpart,foranypurpose.Thisreportisnotdirectedorintendedfordistributionto,oruseby,anypersonorentitywhoisacitizenorresidentoforlocatedin
anylocality,state,countryorotherjurisdiction,wheresuchdistribution,publication,availabilityorusewouldbecontrarytolaw,regulationorwhichwouldEdelweissandaffiliates/group
companiestoanyregistrationorlicensingrequirementswithinsuchjurisdiction.Thedistributionofthisdocumentincertainjurisdictionsmayberestrictedbylaw,andpersonsinwhose
possessionthisdocumentcomes,shouldinformthemselvesaboutandobserve,anysuchrestrictions.Theinformationgiveninthisdocumentisasofthedateofthisreportandtherecan
benoassurancethatfutureresultsoreventswillbeconsistentwiththisinformation.Thisinformationissubjecttochangewithoutanypriornotice.Edelweissreservestherighttomake
modificationsandalterationstothisstatementasmayberequiredfromtimetotime.However,Edelweissisundernoobligationtoupdateorkeeptheinformationcurrent.Nevertheless,
Edelweissiscommittedtoprovidingindependentandtransparentrecommendationtoitsclientandwouldbehappytoprovideanyinformationinresponsetospecificclientqueries.
Neither Edelweiss nor any of its affiliates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or
consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. Past performance is not necessarily a guide to future
performance.PleasenotethatMutualFundInvestmentsaresubjecttomarketrisks,readtheofferdocumentcarefullyoftherespectiveschemesbeforeinvestingforfullunderstanding
and detail. Kindly read the Risk Disclosure Documents carefully before investing in Equity Shares, Derivatives, Commodities or other instruments. The information provided in these
reportsremains,unlessotherwisestated,thecopyrightofEdelweiss.Alllayout,design,originalartwork,conceptsandotherIntellectualProperties,remainsthepropertyandcopyrightof
Edelweissandmaynotbeusedinanyformorforanypurposewhatsoeverbyanypartywithouttheexpresswrittenpermissionofthecopyrightholders.

Theissuer(person/entity/companymakinganofferofspecifiedsecurities)isproposing,subjecttomarketconditionsandotherconsiderations,apublicissueofitsequityshares/bonds/
debenturesandhasfiledtheOfferDocuments/Prospectus/RedHerringProspectuswiththeRegistrarofCompanies(ROC).TheOfferDocuments/Prospectus/RedHerringProspectus
isavailableonthewebsitesofSEBIatwww.sebi.gov.inandatthewebsiteoftheBookRunningLeadManager(s)asmentionedintheOfferDocuments/Prospectus/RedHerringProspectus.

Thisservice/informationisstrictlyconfidentialandisbeingfurnishedtoyousolelyforyourinformation.Thisinformationshouldnotbereproducedorredistributedorpassedondirectly
orindirectlyinanyformtoanyotherpersonorpublished,copied,inwholeorinpart,foranypurpose.Thisservice/informationisnotdirectedorintendedfordistributionto,oruseby,
anypersonorentitywhoisacitizenorresidentoforlocatedinanylocality,state,countryorotherjurisdiction,wheresuchdistribution,publication,availabilityorusewouldbecontrary
to law, regulation or which would subject Edelweiss Web Services Ltd. and affiliates/ group companies to any registration or licensing requirements within such jurisdiction. The
distributionofthisdocumentincertainjurisdictionsmayberestrictedbylaw,andpersonsinwhosepossessionthisdocumentcomes,shouldinformthemselvesaboutandobserve,any
suchrestrictions.

Thedatawouldbeprovidedtotheclientsonan"asis"and"whereis"basis,withoutanywarranty.Edelweissoritssubsidiariesandassociatedcompaniesshallnotbeliableforanydelay
oranyotherinterruptionwhichmayoccurinprovidingthedataduetoanyreasonincludingnetwork(Internet)reasonsorsnagsinthesystem,breakdownofthesystemoranyother
equipment,serverbreakdown,maintenanceshutdown,breakdownofcommunicationservicesorinabilityoftheEdelweissoritssubsidiariesandassociatedcompaniestoprovidethe
data. In no event shall the Edelweiss or its subsidiaries and associated companies be liable for any damages, including without limitation direct or indirect, special, incidental, or

consequentialdamages,lossesorexpensesarisinginconnectionwiththedataprovidedbytheEdelweissoritssubsidiariesandassociatedcompanies.

DisclaimerforU.S.Persons:
EBLisnotaregisteredbrokerdealerundertheU.S.SecuritiesExchangeActof1934,asamended(the1934act)andunderapplicablestatelawsintheUnitedStates.InadditionEBLis
notaregisteredinvestmentadviserundertheU.S.InvestmentAdvisersActof1940,asamended(the"AdvisersAct"andtogetherwiththe1934Act,the"Acts),andunderapplicablestate
lawsintheUnitedStates.Accordingly,intheabsenceofspecificexemptionundertheActs,anybrokerageandinvestmentservicesprovidedbyEBL,includingtheproductsandservices
describedhereinarenotavailabletoorintendedforU.S.persons.Thisemailmessagedoesnotconstituteanofferorinvitationtopurchaseorsubscribeforanysecuritiesorsolicitationof
anyinvestmentsorinvestmentservicesand/orshallnotbeconsideredasanadvertisementtool."U.S.Persons"aregenerallydefinedasanaturalperson,residingintheUnitedStatesor
anyentityorganizedorincorporatedunderthelawsoftheUnitedStates.USCitizenslivingabroadmayalsobedeemed"USPersons"undercertainrules.

DisclaimerforU.K.Persons:
ThecontentsofthismailerhavenotbeenapprovedbyanauthorisedpersonwithinthemeaningoftheFinancialServicesandMarketsAct2000("FSMA").
IntheUnitedKingdom,thismailerisbeingdistributedonlytoandisdirectedonlyat(a)personswhohaveprofessionalexperienceinmattersrelatingtoinvestmentsfallingwithinArticle
19(5)oftheFSMA(FinancialPromotion)Order2005(theOrder);(b)personsfallingwithinArticle49(2)(a)to(d)oftheOrder(includinghighnetworthcompaniesandunincorporated
associations);and(c)anyotherpersonstowhomitmayotherwiselawfullybecommunicated(allsuchpersonstogetherbeingreferredtoasrelevantpersons).
Thismailermustnotbeactedonorreliedonbypersonswhoarenotrelevantpersons.Anyinvestmentorinvestmentactivitytowhichthismailerrelatesisavailableonlytorelevant
personsandwillbeengagedinonlywithrelevantpersons.Anypersonwhoisnotarelevantpersonshouldnotactorrelyonthismailernoranyofitscontents.Thismailermustnotbe
distributed,published,reproducedordisclosed(inwholeorinpart)byrecipientstoanyotherperson.

DisclaimerforCanadianPersons:
EBLisnotaregisteredadviserordealerunderapplicableCanadiansecuritieslawsnorhasitobtainedanexemptionfromtheadviserand/ordealerregistrationrequirementsundersuch
law.Accordingly,anybrokerageandinvestmentservicesprovidedbyEBL,includingtheproductsandservicesdescribedherein,arenotavailabletoorintendedforCanadianpersons.This
maileranditsrespectivecontentsdonotconstituteanofferorinvitationtopurchaseorsubscribeforanysecuritiesorsolicitationofanyinvestmentsorinvestmentservices.